Frontline Ltd. (FRO)
NYSE: FRO
· Real-Time Price · USD
21.82
0.93 (4.45%)
At close: Sep 03, 2025, 3:59 PM
21.26
-2.56%
Pre-market: Sep 04, 2025, 07:19 AM EDT
4.45% (1D)
Bid | 21.5 |
Market Cap | 4.86B |
Revenue (ttm) | 1.9B |
Net Income (ttm) | 348.05M |
EPS (ttm) | 1.08 |
PE Ratio (ttm) | 20.2 |
Forward PE | 7.49 |
Analyst | Buy |
Ask | 21.87 |
Volume | 3,206,959 |
Avg. Volume (20D) | 2,584,008 |
Open | 21.31 |
Previous Close | 20.89 |
Day's Range | 21.19 - 21.84 |
52-Week Range | 12.40 - 25.68 |
Beta | 0.24 |
Analyst Forecast
According to 0 analyst ratings, the average rating for FRO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Frontline has released their quartely earnings
on Aug 29, 2025:
Next Earnings Release
Frontline Ltd. is scheduled to release its earnings on
Nov 26, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+0.66%
Shares of oil-related companies are trading higher...
Unlock content with
Pro Subscription
2 months ago
+0.74%
Shares of oil-related companies are trading higher. The commodity may be seeing a price increase due to a rebound after falling amid escalating Iran-Israel tensions.

1 week ago · seekingalpha.com
Wall Street Week AheadListen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

2 months ago · businesswire.com
Frontline WSIB Workers Rally at Ford's Office Amid Growing Strike TensionsTORONTO--(BUSINESS WIRE)-- #FordNation--Harry Goslin, President of the Ontario Compensation Employees Union (OCEU/CUPE 1750), will join striking Workplace Safety and Insurance Board (WSIB) workers on ...

2 months ago · accessnewswire.com
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML85% remission rate observed in evaluable frontline AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting toxicities observed ...